HealthQuill US
GSK Plc will invest $800 million in Montgomery, Pennsylvania to build a biopharmaceutical innovation and manufacturing hub, according to the state governor Josh Shapiro.
Drugs Medical Pharma

GSK Plc to invest $800 million in Pennsylvania for biopharma hub

GSK Plc will invest $800 million in Montgomery, Pennsylvania to build a biopharmaceutical innovation and manufacturing hub, according to the state governor Josh.

Read More
New York Governor Kathy Hochul declared a state of emergency in the most populous city in the United States over a measles outbreak.
Drugs Health Medical

New York State issues emergency order to fight measles surge

New York Governor Kathy Hochul declared a state of emergency in the most populous city in the United States over a measles outbreak.

Read More
American pharmaceutical company Johnson & Johnson’s investigational drug met its main goal during end-stage trials for the treatment of manic episodes in adults with bipolar I disorder, according to the company.
Drugs Pharma Research

J&J’s test drug for manic episodes in bipolar disorder meets main goal

HQ Team September 22, 2026: American pharmaceutical company Johnson & Johnson’s investigational drug met its main goal during end-stage trials for the treatment.

Read More
The death toll from the Ebola virus, which is sweeping through the heart of the Central African region of the Democratic Republic of the Congo (DRC), has neared 3,500 with about 7,000 confirmed cases, the second-largest Ebola outbreak on record.
Drugs Health Pharma

Death toll in Congo’s worst Ebola virus outbreak set to cross 7,000: CDC says

HQ Team September 14, 2026: The death toll from the Ebola virus, which is sweeping through the heart of the Central African region.

Read More
The European Union approved AstraZeneca Plc and Amgen Inc.’s add-on therapy to treat adults with a chronic inflammatory condition of the nasal passages.
Drugs Health Pharma

AstraZeneca, Amgen’s drug for nasal inflammation gets EU nod

The European Union approved AstraZeneca Plc and Amgen Inc.’s add-on therapy to treat adults with a chronic inflammatory condition of the nasal passages.

Read More
China’s Innovent Biologics and Takeda Pharmaceutical Co. announced a $11.4 billion licensing deal, which will enable the former to speed up the development of its immuno-oncology and antibody-drug conjugate cancer therapies.
Drugs Health Pharma

China’s Innovent, Japan’s Takeda in $11.4 billion deal for cancer therapies

China’s Innovent Biologics and Takeda Pharmaceutical Co. announced a $11.4 billion licensing deal, which will enable the former to speed up the development.

Read More
Zenas BioPharma, Inc. and China’s InnoCare Pharma Limited have inked a $2 billion licensing deal that grants the US-based Zenas global rights to develop and commercialise an investigational drug to treat multiple sclerosis (MS) and other autoimmune diseases.
Drugs Health Pharma

Zenas, InnoCare in $2b licensing deal for MS, autoimmune diseases

Zenas BioPharma, Inc. and China’s InnoCare Pharma Limited have inked a $2 billion licensing deal that grants the US-based Zenas global rights to.

Read More
US regulator rejects Fortress Biotech’s experimental pediatric medicine 
Drugs Medical Pharma

US regulator rejects Fortress Biotech’s experimental pediatric medicine 

The US regulator has declined to approve an experimental pediatric drug of Fortress Biotech Inc., an American biotechnology company, due to certain production.

Read More
Pfizer Inc., a US pharmaceutical company founded in 1849, has signed an agreement with the Trump administration to lower prices of prescription medicines in the North American nation
Drugs Medical Pharma

Pfizer inks deal with Trump to lower price of prescription drugs in US

Pfizer Inc., a US pharmaceutical company founded in 1849, has signed an agreement with the Trump administration to lower prices of prescription medicines.

Read More
Pfizer Inc. will buy Matsera Inc. for $7.3 billion to eye at least four experimental drugs in the rapidly growing obesity market after it scrapped development of its own weight-loss pill in April this year.
Drugs Health Pharma

Pfizer to buy Matsera Inc. for $7.3 billion, eyes 4 anti-obesity drugs

Pfizer Inc. will buy Matsera Inc. for $7.3 billion to eye at least four experimental drugs in the rapidly growing obesity market after.

Read More